ITCI Stock Forecast 2025-2026
Distance to ITCI Price Targets
ITCI Price Momentum
10 Quality Stocks Worth Considering Now
Researching Intra-Cellular (ITCI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ITCI and similar high-potential opportunities.
Latest ITCI Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, ITCI has a neutral consensus with a median price target of $132.00 (ranging from $132.00 to $132.00). Currently trading at $131.69, the median forecast implies a 0.2% upside. This outlook is supported by 3 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Graig Suvannavejh at Mizuho, projecting a 0.2% upside. Conversely, the most conservative target is provided by Graig Suvannavejh at Mizuho, suggesting a 0.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ITCI Analyst Ratings
ITCI Price Target Range
Latest ITCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ITCI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2025 | Mizuho | Graig Suvannavejh | Neutral | Downgrade | $132.00 |
| Feb 21, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Jan 31, 2025 | Canaccord Genuity | Sumant Kulkarni | Hold | Downgrade | $132.00 |
| Jan 22, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $132.00 |
| Jan 14, 2025 | Piper Sandler | David Amsellem | Neutral | Downgrade | $132.00 |
| Jan 13, 2025 | Needham | Ami Fadia | Hold | Downgrade | $100.00 |
| Nov 4, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $89.00 |
| Oct 31, 2024 | Needham | Ami Fadia | Buy | Reiterates | $100.00 |
| Oct 30, 2024 | Needham | Ami Fadia | Buy | Reiterates | $100.00 |
| Oct 11, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $95.00 |
| Oct 4, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $108.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $130.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $130.00 |
| Sep 6, 2024 | Piper Sandler | Charles Duncan | Overweight | Upgrade | $92.00 |
| Aug 21, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $81.00 |
| Aug 8, 2024 | Needham | Ami Fadia | Buy | Reiterates | $100.00 |
| Aug 8, 2024 | UBS | Ashwani Verma | Neutral | Maintains | $79.00 |
| Aug 8, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $106.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $130.00 |
| Aug 8, 2024 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $74.00 |
Intra-Cellular Therapies Inc. (ITCI) Competitors
The following stocks are similar to Intra-Cellular based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intra-Cellular Therapies Inc. (ITCI) Financial Data
Intra-Cellular Therapies Inc. has a market capitalization of $14.03B with a P/E ratio of -183.0x. The company generates $680.85M in trailing twelve-month revenue with a -11.0% profit margin.
Revenue growth is +50.8% quarter-over-quarter, while maintaining an operating margin of -14.7% and return on equity of -8.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Intra-Cellular Therapies Inc. (ITCI) Business Model
About Intra-Cellular Therapies Inc.
Develops drugs for psychiatric and neurological disorders.
The company generates revenue through the research, development, and commercialization of innovative therapies that target specific neuronal signaling mechanisms. By focusing on complex psychiatric and neurological disorders, it aims to provide effective treatment options that can improve patient outcomes.
Intra-Cellular Therapies Inc. is positioned as a key player in the healthcare sector, with a commitment to advancing medical science and addressing unmet clinical needs. Its focus on novel drug development not only aims to enhance the quality of life for patients but also contributes to the broader pharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
860
CEO
Dr. Sharon Mates Ph.D.
Country
United States
IPO Year
2014
Website
www.intracellulartherapies.comIntra-Cellular Therapies Inc. (ITCI) Latest News & Analysis
Intra-Cellular's Q4 2024 results show earnings missed estimates, while revenues exceeded expectations due to strong sales of Caplyta.
Mixed results indicate potential volatility; missing earnings may signal concerns about profitability, while strong revenue from Caplyta suggests growth potential and market demand.
Halper Sadeh LLC is investigating the fairness of Johnson & Johnson's $132.00 per share cash offer for Intra-Cellular Therapies (NASDAQ: ITCI) for its shareholders.
The investigation into Intra-Cellular's sale to Johnson & Johnson raises concerns about the fairness of the buyout price, potentially affecting shareholder value and market perception.
Kahn Swick & Foti, LLC is investigating the proposed sale of Intra-Cellular Therapies, Inc. to Johnson & Johnson for $132 per share to assess the fairness of the transaction.
The investigation into Intra-Cellular's sale to Johnson & Johnson could impact stock prices, shareholder sentiment, and the perceived fairness of the acquisition offer.
CAPLYTA's Q4 2024 net product sales reached $199.2 million, marking a 51% increase from Q4 2023.
Strong growth in CAPLYTA sales signals robust demand and can enhance the company's revenue outlook, potentially boosting stock prices and attracting investor interest.
Intra-Cellular Therapies (ITCI) reported a Q3 loss of $0.16 per share, exceeding the expected loss of $0.05, compared to a loss of $0.30 per share last year.
Intra-Cellular Therapies' larger-than-expected loss may raise concerns about its financial health, potentially impacting stock performance and investor confidence.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
2 months agoIn 2025, biotech and pharma dealmaking is strong, while 2024 saw notable fundraising in digital health characterized by a "David and Goliath dynamic."
Strong biotech and pharma deal activity signals confidence and growth potential in the sector. Digital health fundraising trends indicate competitive dynamics that could impact investment strategies.
Frequently Asked Questions About ITCI Stock
What is Intra-Cellular Therapies Inc.'s (ITCI) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Intra-Cellular Therapies Inc. (ITCI) has a median price target of $132.00. The highest price target is $132.00 and the lowest is $132.00.
Is ITCI stock a good investment in 2025?
According to current analyst ratings, ITCI has 3 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $131.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ITCI stock?
Wall Street analysts predict ITCI stock could reach $132.00 in the next 12 months. This represents a 0.2% increase from the current price of $131.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intra-Cellular Therapies Inc.'s business model?
The company generates revenue through the research, development, and commercialization of innovative therapies that target specific neuronal signaling mechanisms. By focusing on complex psychiatric and neurological disorders, it aims to provide effective treatment options that can improve patient outcomes.
What is the highest forecasted price for ITCI Intra-Cellular Therapies Inc.?
The highest price target for ITCI is $132.00 from Graig Suvannavejh at Mizuho, which represents a 0.2% increase from the current price of $131.69.
What is the lowest forecasted price for ITCI Intra-Cellular Therapies Inc.?
The lowest price target for ITCI is $132.00 from Graig Suvannavejh at Mizuho, which represents a 0.2% increase from the current price of $131.69.
What is the overall ITCI consensus from analysts for Intra-Cellular Therapies Inc.?
The overall analyst consensus for ITCI is neutral. Out of 17 Wall Street analysts, 3 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $132.00.
How accurate are ITCI stock price projections?
Stock price projections, including those for Intra-Cellular Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
